
Re Syfovre: ‘It’s a Healthy Debate. It’s a Debate We Should Be Having’ | Charles Wykoff, M.D., Ph.D.
Pros and cons of Syfovre (pegcetacoplan), the newly approved drug for geographic atrophy will be discussed at the American Society of Retinal Specialists annual scientific meeting in Seattle this weekend, predicts leading member of the society. Biosimilars are also on the agenda.
























